Showing results (1531-1540 of 1,679) with videos related to
Sort By:
Pageof 168
Biorxiv : the Preprint Server for Biology|August 6, 2025
The Cornea Harbors a Tricellular Neuro-Immune Niche that Underpins Touch SensationS Littleton, E M Jacob, Yu Chen, et al.Molecular Pharmacology|December 1, 1996
Novel nonpeptide agents potently block the C-type inactivated conformation of Kv1.3 and suppress T cell activationA Nguyen, J C Kath, D C Hanson, et al.Natural Product Research|June 21, 2022
In vitro and in silico antioxidant and α-glucosidase inhibitory potential of compounds isolated from <i>Garcinia gaudichaudii</i>Le-Thu T Nguyen, Chau-Phi Dinh, Phuong T D Nguyen, et al.Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|June 19, 2018
A Randomized Controlled Trial of Balloon Dilation as a Treatment for Persistent Eustachian Tube Dysfunction With 1-Year Follow-UpTed A Meyer, Ellen M O'Malley, Rodney J Schlosser, et al.Cancer Research Communications|October 11, 2023
PSGL-1 Blockade Induces Classical Activation of Human Tumor-associated MacrophagesKevin Kauffman, Denise Manfra, Dominika Nowakowska, et al.American Journal of Rhinology & Allergy|April 30, 2020
A Community-Based Study on the Prevalence of Olfactory DysfunctionRodney J Schlosser, Vincent M Desiato, Kristina A Storck, et al.Stroke (Hoboken, N.J.)|January 26, 2026
Safety and Efficacy of Radial Versus Femoral Artery Access for Mechanical Thrombectomy Procedures Following Intravenous Administration of Tissue Plasminogen ActivatorJoshua S Catapano, Kavelin Rumalla, Dara S Farhadi, et al.European Journal of Cancer (Oxford, England : 1990)|February 29, 2024
A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinomaT Enzler, A Nguyen, J Misleh, et al.Journal for Immunotherapy of Cancer|June 8, 2026
First-in-human, phase 1, open-label study of alomfilimab, an anti-ICOS antibody, as a single agent and in combination with anti-PD-L1 in advanced malignanciesAung Naing, Chia-Chi Lin, Manish R Patel, et al.European Journal of Medicinal Chemistry|April 16, 2021
Azetidinimines as a novel series of non-covalent broad-spectrum inhibitors of β-lactamases with submicromolar activities against carbapenemases KPC-2 (class A), NDM-1 (class B) and OXA-48 (class D)Eugénie Romero, Saoussen Oueslati, Mohamed Benchekroun, et al.Pageof 168